MURINE ANTI-ID ANTIBODIES FOR IMMUNOTHERAPY OF MELANOMA

该计划的长期目标是开发和销售鼠标 抗独特型(抗id)单抗(MOAB) 人高分子黑色素瘤相关抗原的内成像 (HMW-MAA)用于黑色素瘤患者的主动特异性免疫治疗。 这一建议源于对BALB/c小鼠的研究，该研究表明 与KLH的结合和辅助剂的给药明显 增强小鼠抗id抗体MK2-23诱导体液免疫的能力 以及对HMW-MAA的细胞免疫。这一行动的具体目标是 建议确定与KLH和/或结合的效果 卡介苗给药小鼠抗id单抗MK2-23 HMW-MAA在体液抗HMW-MAA诱导中的内成像 黑色素瘤患者的免疫功能及其与肿瘤发生的相关性 抗HMW-MAA免疫与疾病的临床病程有关。数据 迄今为止在小鼠研究和有限的临床试验中获得的数据表明 对体内携带抗id摩押的人进行免疫 HMW-MAA的图像可以诱导对该抗原的特异性免疫反应。 此外，临床试验表明， 抗HMW-MAA免疫和延长患者生存期。这些 调查旨在通过以下方式优化免疫方案 反id摩押，并为其可行性提供进一步的证据 黑色素瘤患者主动特异性免疫治疗的探讨

The long range goal of this program is to develop and market mouse antiidiotypic (anti-id) monoclonal antibodies (MoAb) which bear the internal image of human high molecular weight-melanoma associated antigen (HMW-MAA) for active specific immunotherapy in patients with melanoma. This proposal stems from investigations in BALB/c mice which have shown that conjugation to KLH and administration with an adjuvant markedly enhances the ability of the mouse anti-id MoAb MK2-23 to induce humoral and cellular immunity towards the HMW-MAA. The specific goal of this proposal is to determine the effect of conjugation with KLH and/or administration with BCG of mouse anti-id MoAb MK2-23 (which bears the internal image of HMW-MAA) on the induction of humoral anti HMW-MAA immunity in patients with melanoma and to correlate the development of anti HMW-MAA immunity with the clinical course of the disease. The data obtained to date in mouse studies and limited clinical trials indicate that immunization of individuals with anti-id MoAb bearing the internal image of HMW-MAA can induce specific immune responses to this antigen. Moreover, the clinical trials have demonstrated an association between anti HMW-MAA immunity and prolonged patient survival. These investigations are designed to optimize the immunization protocols with anti-id MoAb and provide further evidence for the feasibility of this approach in the active specific immunotherapy of patients with melanoma.